Abstract

Microcystins (MC) and nodularin (NOD) are toxins released by cyanobacteria during harmful algal blooms. They are potent inhibitors of protein phosphatases 1 and 2A (PP1 and PP2A) and cause a variety of adverse symptoms in humans and animals if ingested. More than 250 chemically diverse congeners of MCs have been identified, but certified reference materials are only available for a few. A diagnostic test that does not require each reference material for detection is necessary to identify human exposures. To address this need, our lab has developed a method that uses an antibody to specifically isolate MCs and NOD from urine prior to detection via a commercially available PP2A kit. This assay quantitates the summed inhibitory activity of nearly all MCs and NOD on PP2A relative to a common MC congener, microcystin-LR (MC-LR). The quantitation range for MC-LR using this method is from 0.050–0.500 ng/mL. No background responses were detected in a convenience set of 50 individual urines. Interday and intraday % accuracies ranged from 94%–118% and relative standard deviations were 15% or less, meeting FDA guidelines for receptor binding assays. The assay detected low levels of MCs in urines from three individuals living in close proximity to harmful algal blooms (HABs) in Florida.

Highlights

  • Cyanobacteria are ubiquitous photosynthetic bacteria commonly found in freshwater systems worldwide

  • Key Contribution: This paper describes the development and subsequent validation of an immunocapture-protein phosphatase inhibition assay to detect and measure combined inhibitory activity of MCs and NOD in human urine

  • Our lab previously described a method for detection of MC-LR in human urine by (IC) liquid chromatography tandem mass spectrometry [26]

Read more

Summary

Introduction

Cyanobacteria are ubiquitous photosynthetic bacteria commonly found in freshwater systems worldwide. During HABs, species of cyanobacteria release toxic peptides, including microcystins (MCs) and nodularin (NOD), into waterways [1]. MCs a variety of routes including ingestion, direct skin haemodialysis, or inhalation [3]. The developed immunocapture protein phosphatase phosphatase inhibition inhibition assay (IC-PPIA) uses an adda-specific antibody to capture and 10-fold concentrate only MCs and NOD from urine prior to PPIA toxicity toxicity measurements measurements relative relative to to MC-LR.

Method Optimization
Method
Specificity
Validation of MC-LR
Analysis of Urine Samples from Florida Residents
Discussion
Materials
Biological Specimens
Mass Spectrometry Conditions
Liquid Chromatography Conditions
MC IC Protocol
Protein Phosphatase Inhibition Assay
Data Analysis
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.